Please login to the form below

Not currently logged in
Email:
Password:

Novo Nordisk addresses Mixtard 30 concerns

Novo Nordisk has responded to a claim that the company is planning to remove insulin, Mixtard 30, from the UK market

Novo Nordisk has responded to an exclusive story published in the Herald Scotland on June 9, which claimed the company is planning to remove insulin, Mixtard 30, from the UK market. 

According to the newspaper, the removal of Mixtard 30 would result in thousands of diabetic patients facing a change of medication and would place undue burden on the NHS.

Head of policy at Diabetes UK, Bridget Turner, commented that the removal of any insulin from the market goes against patient choice and will cause anxiety for people with diabetes.

"If there are any changes to the types of insulin available in the UK, pharmaceutical companies have a duty of care to provide time for those affected to liaise with their healthcare teams to discuss alternative treatments," Turner said.

Responding to a request for clarity regarding the article, the Danish drug maker stated that it had not made any announcements regarding Mixtard 30. "Novo Nordisk continually reviews its insulin portfolio as newer more innovative insulins are introduced. This has resulted in a gradual discontinuation of older animal and human insulins as modern insulins have become established in the UK," it said.

Novo Nordisk also said that any insulin portfolio changes would be communicated in "a timely and professional manner".

"We believe it is imperative that any communication is done in a way that minimises patient concern and ensures that healthcare professionals have the appropriate information to discuss the impact of any change with their individual patients and provide support and reassurance as needed," the spokesperson added.

11th June 2010

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Research Partnership

We are the largest independent healthcare market research and consulting agencies in the world. Trusted partner to the global pharmaceutical...

Latest intelligence

Report: Achieving launch excellence in the challenging healthcare markets of today
Our in-depth report is based on original data and expert interviews, which coupled with our own experience, ensures we give you the best recommendations for achieving launch success in challenging...
What is blockchain and why should i care - Richard Springham
Four Health - Emerging Technologies The power of blockchain lies in the fact it can prove that a unique event occurred at a certain time with out the need to...
NHS medicines optimisation milestone
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare Consulting Team, explore the implications of Adalimumab’s recent European patent expiry...

Infographics